Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1991 Jul;35(7):1448–1453. doi: 10.1128/aac.35.7.1448

Aerosol and intraperitoneal administration of ribavirin and ribavirin triacetate: pharmacokinetics and protection of mice against intracerebral infection with influenza A/WSN virus.

B E Gilbert 1, P R Wyde 1, S Z Wilson 1, R K Robins 1
PMCID: PMC245188  PMID: 1929307

Abstract

Ribavirin is active in vitro but not in vivo against a number of viruses capable of causing encephalitis. Ribavirin triacetate (RTA), a lipophilic derivative, has been reported to be more effective than ribavirin in protecting animals from encephalitis. By using an influenza A/WSN virus encephalitis model, we demonstrated that RTA administered by small-particle aerosol was able to decrease the death rate and increase the time of survival. To determine if this beneficial effect was due to increased delivery of drug, the pharmacokinetic properties of ribavirin and RTA when administered as an aerosol or by intraperitoneal injection were examined. Aerosol administration of ribavirin or RTA gave significantly higher concentrations of ribavirin in the lungs and serum of mice than did intraperitoneal injection. There was no difference, however, in ribavirin levels when either ribavirin or RTA was administered by small-particle aerosol. In brain tissue, ribavirin concentrations increased with time and did not appear to decrease as rapidly as in lungs and serum. Mean peak ribavirin concentrations in the brain were higher following aerosol administration of ribavirin than RTA, and both were higher than that following intraperitoneal injection of either drug. Administration of ribavirin or RTA by intraperitoneal injection failed to protect mice from a lethal intracerebral inoculation of influenza A/WSN virus, while aerosolized RTA did protect mice. The pharmacokinetics of ribavirin in brain tissue following aerosol administration of either drug did not explain the advantage of RTA over ribavirin in protecting mice from intracerebral infection with influenza A/WSN virus.

Full text

PDF
1448

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Crumpacker C., Bubley G., Lucey D., Hussey S., Connor J. Ribavirin enters cerebrospinal fluid. Lancet. 1986 Jul 5;2(8497):45–46. doi: 10.1016/s0140-6736(86)92590-0. [DOI] [PubMed] [Google Scholar]
  2. Gilbert B. E., Knight V. Biochemistry and clinical applications of ribavirin. Antimicrob Agents Chemother. 1986 Aug;30(2):201–205. doi: 10.1128/aac.30.2.201. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Gilbert B. E., Wyde P. R. Pharmacokinetics of ribavirin aerosol in mice. Antimicrob Agents Chemother. 1988 Jan;32(1):117–121. doi: 10.1128/aac.32.1.117. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Huggins J. W., Kim G. R., Brand O. M., McKee K. T., Jr Ribavirin therapy for Hantaan virus infection in suckling mice. J Infect Dis. 1986 Mar;153(3):489–497. doi: 10.1093/infdis/153.3.489. [DOI] [PubMed] [Google Scholar]
  5. Kenyon R. H., Canonico P. G., Green D. E., Peters C. J. Effect of ribavirin and tributylribavirin on argentine hemorrhagic fever (Junin virus) in guinea pigs. Antimicrob Agents Chemother. 1986 Mar;29(3):521–523. doi: 10.1128/aac.29.3.521. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Knight V., Wilson S. Z., Alling D. W., Moore R. V., Longoria R. M. Lack of interference of guanosine with ribavirin aerosol treatment of influenza A infection in mice. Antimicrob Agents Chemother. 1981 Oct;20(4):477–480. doi: 10.1128/aac.20.4.477. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Koff W. C., Pratt R. D., Elm J. L., Jr, Venkateshan C. N., Halstead S. B. Treatment of intracranial dengue virus infections in mice with a lipophilic derivative of ribavirin. Antimicrob Agents Chemother. 1983 Jul;24(1):134–136. doi: 10.1128/aac.24.1.134. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Malinoski F. J., Hasty S. E., Ussery M. A., Dalrymple J. M. Prophylactic ribavirin treatment of dengue type 1 infection in rhesus monkeys. Antiviral Res. 1990 Mar;13(3):139–149. doi: 10.1016/0166-3542(90)90029-7. [DOI] [PubMed] [Google Scholar]
  9. McKee K. T., Jr, Huggins J. W., Trahan C. J., Mahlandt B. G. Ribavirin prophylaxis and therapy for experimental argentine hemorrhagic fever. Antimicrob Agents Chemother. 1988 Sep;32(9):1304–1309. doi: 10.1128/aac.32.9.1304. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Ogle J. W., Toltzis P., Parker W. D., Alvarez N., McIntosh K., Levin M. J., Lauer B. A. Oral ribavirin therapy for subacute sclerosing panencephalitis. J Infect Dis. 1989 Apr;159(4):748–750. doi: 10.1093/infdis/159.4.748. [DOI] [PubMed] [Google Scholar]
  11. Sidwell R. W., Allen L. B., Khare G. P., Huffman J. H., Witkowski J. T., Simon L. N., Robins R. K. Effect of 1-beta-D-ribofuranosyl1-1,2,4-triazole-3-carboxamide (virazole, ICN 1229) on herpes and vaccinia keratitis and encephalitis in laboratory animals. Antimicrob Agents Chemother. 1973 Feb;3(2):242–246. doi: 10.1128/aac.3.2.242. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Sidwell R. W., Huffman J. H., Barnard D. L., Pifat D. Y. Effects of ribamidine, a 3-carboxamidine derivative of ribavirin, on experimentally induced Phlebovirus infections. Antiviral Res. 1988 Dec 1;10(4-5):193–207. doi: 10.1016/0166-3542(88)90031-9. [DOI] [PubMed] [Google Scholar]
  13. Sidwell R. W., Huffman J. H., Barnett B. B., Pifat D. Y. In vitro and in vivo Phlebovirus inhibition by ribavirin. Antimicrob Agents Chemother. 1988 Mar;32(3):331–336. doi: 10.1128/aac.32.3.331. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Smith R. H., Gilbert B. E. Quantification of ribavirin in biological fluids and tissues by high-performance liquid chromatography. J Chromatogr. 1987 Feb 20;414(1):202–210. doi: 10.1016/0378-4347(87)80042-7. [DOI] [PubMed] [Google Scholar]
  15. Wilson S. Z., Knight V., Wyde P. R., Drake S., Couch R. B. Amantadine and ribavirin aerosol treatment of influenza A and B infection in mice. Antimicrob Agents Chemother. 1980 Apr;17(4):642–648. doi: 10.1128/aac.17.4.642. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Wyde P. R., Gilbert B. E., Levy B. M. Evidence that T-lymphocytes are part of the blood-brain barrier to virus dissemination. J Neuroimmunol. 1983 Aug;5(1):47–58. doi: 10.1016/0165-5728(83)90025-5. [DOI] [PubMed] [Google Scholar]
  17. Wyde P. R., Wilson S. Z., Gilbert B. E., Smith R. H. Protection of mice from lethal influenza virus infection with high dose-short duration ribavirin aerosol. Antimicrob Agents Chemother. 1986 Dec;30(6):942–944. doi: 10.1128/aac.30.6.942. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Wyde P. R., Wilson S. Z., Petrella R., Gilbert B. E. Efficacy of high dose-short duration ribavirin aerosol in the treatment of respiratory syncytial virus infected cotton rats and influenza B virus infected mice. Antiviral Res. 1987 May;7(4):211–220. doi: 10.1016/0166-3542(87)90029-5. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES